EA201991497A1 - Производные бензодиазепина, композиции и способы лечения когнитивного нарушения - Google Patents
Производные бензодиазепина, композиции и способы лечения когнитивного нарушенияInfo
- Publication number
- EA201991497A1 EA201991497A1 EA201991497A EA201991497A EA201991497A1 EA 201991497 A1 EA201991497 A1 EA 201991497A1 EA 201991497 A EA201991497 A EA 201991497A EA 201991497 A EA201991497 A EA 201991497A EA 201991497 A1 EA201991497 A1 EA 201991497A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cognitive impairment
- treatment
- gaba receptor
- age
- compositions
- Prior art date
Links
- 208000028698 Cognitive impairment Diseases 0.000 title abstract 7
- 208000010877 cognitive disease Diseases 0.000 title abstract 7
- 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 title abstract 3
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 4
- 208000024827 Alzheimer disease Diseases 0.000 abstract 3
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 abstract 2
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 2
- 102000005915 GABA Receptors Human genes 0.000 abstract 2
- 108010005551 GABA Receptors Proteins 0.000 abstract 2
- 229940121909 GABA receptor agonist Drugs 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 229940126027 positive allosteric modulator Drugs 0.000 abstract 2
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000001914 Fragile X syndrome Diseases 0.000 abstract 1
- 208000000172 Medulloblastoma Diseases 0.000 abstract 1
- 208000036626 Mental retardation Diseases 0.000 abstract 1
- 230000007000 age related cognitive decline Effects 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 231100000867 compulsive behavior Toxicity 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 206010027175 memory impairment Diseases 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Настоящее изобретение относится к производным бензодиазепина, композициям, содержащим терапевтически эффективные количества производных бензодиазепина, и способам применения данных производных или композиций для лечения когнитивного нарушения, связанного с нарушениями центральной нервной системы (ЦНС). В частности, оно относится к применению агониста α5-содержащего ГАМК-рецептора (например, положительного аллостерического модулятора α5-содержащего ГАМК-рецептора), как описано в настоящей заявке, для лечения когнитивного нарушения, связанного с нарушениями центральной нервной системы (ЦНС), у объекта, нуждающегося в таком лечении или с риском развития, включая, но не ограничиваясь ими, объекты, имеющие или подверженные риску равзвития возрастного когнитивного нарушения, умеренного когнитивного нарушения (УКН), амнестического УКН (аУКН), возрастного нарушения памяти (ВНП), возрастного снижения когнитивных функций (ВСКФ), деменции, болезни Альцгеймера (БА), продромального периода БА, посттравматического стрессового расстройства (ПТСР), шизофрении, биполярного расстройства, бокового амиотрофического склероза (БАС), связанного с терапией рака когнитивного нарушения, умственной отсталости, болезни Паркинсона (БП), расстройств аутистического спектра, синдрома ломкой X-хромосомы, синдрома Ретта, компульсивного поведения и наркотической зависимости. Оно также относится к применению агониста α5-содержащего ГАМК-рецептора (например, положительного аллостерического модулятора α5-содержащего ГАМК-рецептора), как описано в настоящей заявке, для лечения рака головного мозга (включая опухоли головного мозга, например медуллобластомы) и связанных с ним когнитивных нарушений.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662436272P | 2016-12-19 | 2016-12-19 | |
| PCT/IB2017/001762 WO2018130868A1 (en) | 2016-12-19 | 2017-12-20 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| PCT/IB2017/001763 WO2018130869A1 (en) | 2016-12-19 | 2017-12-20 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201991497A1 true EA201991497A1 (ru) | 2020-01-20 |
Family
ID=62557208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201991497A EA201991497A1 (ru) | 2016-12-19 | 2017-12-20 | Производные бензодиазепина, композиции и способы лечения когнитивного нарушения |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20180170941A1 (ru) |
| EP (1) | EP3555100B1 (ru) |
| JP (1) | JP7153938B2 (ru) |
| CN (2) | CN116640143A (ru) |
| AU (1) | AU2017393082B2 (ru) |
| CA (1) | CA3047684A1 (ru) |
| EA (1) | EA201991497A1 (ru) |
| IL (1) | IL267451B2 (ru) |
| MX (1) | MX2019007338A (ru) |
| WO (2) | WO2018130869A1 (ru) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ722077A (en) | 2013-12-20 | 2021-12-24 | Agenebio Inc | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| IL256354B (en) | 2015-06-19 | 2022-09-01 | Agenebio Inc | History of benzodiazepines, preparations and their use for the treatment of cognitive impairment |
| US11505555B2 (en) | 2016-12-19 | 2022-11-22 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| MX2020013927A (es) * | 2018-06-19 | 2021-03-02 | Agenebio Inc | Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo. |
| US11485734B2 (en) | 2018-10-02 | 2022-11-01 | Northwestern University | Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2C (5-HT2C) |
| EP4077333A4 (en) * | 2019-12-19 | 2024-01-10 | Agenebio, Inc. | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS |
| CA3185573A1 (en) * | 2020-07-10 | 2022-01-13 | Deepa GANDLA | Polymorphs of a gabaa .alpha.5 agonist and methods of using in the treatment of cognitive impairment |
| CN116075302A (zh) * | 2020-07-10 | 2023-05-05 | 艾吉因生物股份有限公司 | GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法 |
| CN113413532B (zh) * | 2021-07-01 | 2022-03-01 | 曾迎春 | 基于虚拟现实的癌症相关认知障碍评估与康复训练系统 |
| WO2024039886A1 (en) | 2022-08-19 | 2024-02-22 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3391142A (en) | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
| US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| NL7305644A (ru) | 1972-04-20 | 1973-10-23 | ||
| NL7605526A (nl) | 1976-05-24 | 1977-11-28 | Akzo Nv | Nieuwe tetracyclische derivaten. |
| JPS54130587A (en) | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
| US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| IE58370B1 (en) | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
| GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US4816456A (en) | 1986-10-01 | 1989-03-28 | Summers William K | Administration of monoamine acridines in cholinergic neuronal deficit states |
| HU201906B (en) | 1987-03-04 | 1991-01-28 | Sandoz Ag | Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| CA2000786C (en) | 1988-11-07 | 1999-01-26 | Cornelus G. M. Janssen | 3-piperidinyl-1,2-benzisoxazoles |
| US5043345A (en) | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
| DE58905637D1 (de) | 1989-04-14 | 1993-10-21 | Merz & Co Gmbh & Co | Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie. |
| ES2076253T3 (es) | 1989-05-19 | 1995-11-01 | Hoechst Roussel Pharma | N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos. |
| US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| JP2807577B2 (ja) | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
| JP2800953B2 (ja) | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
| US5190951A (en) | 1990-10-19 | 1993-03-02 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| US5106856A (en) | 1991-06-07 | 1992-04-21 | Hoechst-Roussel Pharmaceuticals Inc. | [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds |
| TW201311B (ru) * | 1991-06-17 | 1993-03-01 | Hoffmann La Roche | |
| US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| NZ282394A (en) | 1994-03-02 | 1997-12-19 | Akzo Nobel Nv | Dissolving tablets contain a dibenz[2,3:6,7] oxepino[4,5-c]pyrrole derivative for sublingual or buccal administration |
| US6479523B1 (en) | 1997-08-26 | 2002-11-12 | Emory University | Pharmacologic drug combination in vagal-induced asystole |
| DE60014043T2 (de) | 1999-03-03 | 2005-09-29 | Eisai Co., Ltd. | Flouride von 4-substituierten piperidin-derivaten |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US20020151591A1 (en) | 2000-10-17 | 2002-10-17 | Anabella Villalobos | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders |
| TWI239333B (en) * | 2000-11-16 | 2005-09-11 | Hoffmann La Roche | Benzodiazepine derivatives as GABA A receptor modulators |
| PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| US7635709B2 (en) | 2002-09-26 | 2009-12-22 | The United States Of America As Represented By The Department Of Veterans Affairs | Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction |
| CN100339070C (zh) | 2002-10-24 | 2007-09-26 | 莫茨药物股份两合公司 | 包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物 |
| CA2506194A1 (en) | 2002-11-22 | 2004-06-10 | The Johns Hopkins University | Target for therapy of cognitive impairment |
| EP1682109B1 (en) | 2003-10-22 | 2008-10-15 | Merz Pharma GmbH & Co. KGaA | The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic as peptides in amyloidopathies |
| MX2007004250A (es) * | 2004-10-12 | 2007-06-12 | Hoffmann La Roche | Derivados de imidazo[1,5-a]triazolo[1,5-d]benzodiazepina para el tratamiento de trastornos cognitivos. |
| WO2006045429A1 (en) * | 2004-10-20 | 2006-05-04 | F. Hoffmann-La Roche Ag | Halogen substituted benzodiazepine derivatives |
| NZ554439A (en) * | 2004-10-20 | 2009-09-25 | Hoffmann La Roche | Imidazo-benzodiazepine derivatives |
| ES2307230T3 (es) * | 2004-12-14 | 2008-11-16 | F. Hoffmann-La Roche Ag | Imidazo-benzodiacepinas tetraciclicas como moduladores de los receptores gaba. |
| US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| EP1924712B1 (en) | 2005-08-03 | 2018-10-03 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| AU2009277086B2 (en) | 2008-08-01 | 2015-12-10 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
| KR20110066952A (ko) | 2008-09-25 | 2011-06-17 | 비브 나노, 인코포레이티드 | 중합체 나노입자 및 활성 성분의 제형을 제조하는 방법 |
| US8853219B2 (en) | 2010-01-11 | 2014-10-07 | Neurosolis, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
| NZ608592A (en) * | 2010-11-05 | 2015-08-28 | Hoffmann La Roche | Use of active pharmaceutical compounds for the treatment of central nervous system conditions |
| CA2817988A1 (en) * | 2010-11-15 | 2012-05-24 | Agenebio, Inc. | Benzodiazepine derivatives, compositions and methods for treating cognitive impairment |
| US20150374705A1 (en) * | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| EP2892521A4 (en) | 2012-09-10 | 2016-06-29 | Ophirex Inc | ADMINISTRATION OF ACETYLCHOLINESTERASE INHIBITORS FOR THE ALLOCATION OF NEUROTOXININDUCED FLUCTUATIONS AND THE REMAINING NEUROMUSCULAR BLOCKADES |
| NZ722077A (en) * | 2013-12-20 | 2021-12-24 | Agenebio Inc | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| IL256354B (en) * | 2015-06-19 | 2022-09-01 | Agenebio Inc | History of benzodiazepines, preparations and their use for the treatment of cognitive impairment |
-
2017
- 2017-12-19 US US15/847,906 patent/US20180170941A1/en not_active Abandoned
- 2017-12-20 WO PCT/IB2017/001763 patent/WO2018130869A1/en active Application Filing
- 2017-12-20 CA CA3047684A patent/CA3047684A1/en active Pending
- 2017-12-20 AU AU2017393082A patent/AU2017393082B2/en active Active
- 2017-12-20 CN CN202310213936.1A patent/CN116640143A/zh active Pending
- 2017-12-20 IL IL267451A patent/IL267451B2/en unknown
- 2017-12-20 EA EA201991497A patent/EA201991497A1/ru unknown
- 2017-12-20 EP EP17891696.1A patent/EP3555100B1/en active Active
- 2017-12-20 CN CN201780086584.0A patent/CN110382501A/zh active Pending
- 2017-12-20 JP JP2019554038A patent/JP7153938B2/ja active Active
- 2017-12-20 WO PCT/IB2017/001762 patent/WO2018130868A1/en unknown
- 2017-12-20 MX MX2019007338A patent/MX2019007338A/es unknown
-
2022
- 2022-09-02 US US17/902,374 patent/US20230134844A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL267451B1 (en) | 2023-06-01 |
| EP3555100B1 (en) | 2023-05-10 |
| JP7153938B2 (ja) | 2022-10-17 |
| US20180170941A1 (en) | 2018-06-21 |
| EP3555100A4 (en) | 2020-06-10 |
| WO2018130868A1 (en) | 2018-07-19 |
| EP3555100A1 (en) | 2019-10-23 |
| WO2018130868A8 (en) | 2019-08-08 |
| JP2020512389A (ja) | 2020-04-23 |
| AU2017393082A1 (en) | 2019-07-25 |
| MX2019007338A (es) | 2019-09-19 |
| IL267451A (en) | 2019-08-29 |
| CN110382501A (zh) | 2019-10-25 |
| US20230134844A1 (en) | 2023-05-04 |
| WO2018130869A1 (en) | 2018-07-19 |
| AU2017393082B2 (en) | 2022-04-21 |
| CN116640143A (zh) | 2023-08-25 |
| IL267451B2 (en) | 2023-10-01 |
| CA3047684A1 (en) | 2018-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201991497A1 (ru) | Производные бензодиазепина, композиции и способы лечения когнитивного нарушения | |
| MX2019010577A (es) | Derivados de benzodiazepina, composiciones, y metodos para tratar el deterioro cognitivo. | |
| EA202190076A1 (ru) | Производные бензодиазепина, композиции и способы лечения когнитивных нарушений | |
| MX2017015752A (es) | Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo. | |
| GEP20207149B (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| EA201390710A1 (ru) | Производные бензодиазепина, композиции и способы для лечения когнитивного нарушения | |
| MA39219A1 (fr) | Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique | |
| GEP20227446B (en) | New catecholamine prodrugs for use in treatment of parkinson's disease | |
| NZ713762A (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| MX2022007725A (es) | Derivados de benzodiazepinas, composiciones y metodos para tratar deterioro cognitivo. | |
| EA201691529A1 (ru) | Гетероарильные амиды в качестве ингибиторов агрегации белков | |
| MX2019004859A (es) | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. | |
| EA201390712A1 (ru) | Производные пиридазина, композиции и способы лечения когнитивного нарушения | |
| MX2017008083A (es) | Compuestos 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2h-pirrol-5-amina inhibidores de beta-secretasa. | |
| EA201990450A1 (ru) | Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
| BR112020022088A8 (pt) | Moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolina | |
| BR112023000423A2 (pt) | Combinações de agonistas gabaa alfa 5 e inibidores de sv2a e métodos de uso no tratamento de comprometimento cognitivo | |
| EA201990399A1 (ru) | Соединения, композиции и их применение | |
| IN2013DN11328A (ru) | ||
| EA201890769A1 (ru) | Производные 2,3,4,5-тетрагидропиридин-6-амина | |
| EA201691290A1 (ru) | Бензодиазепиновые производные, композиции и способы для лечения когнитивного нарушения | |
| MX2019002125A (es) | Derivados de hidroxinorketamina para el tratamiento de trastornos. | |
| FI3541784T3 (fi) | Uudet atsetidiinijohdannaiset, jotka ovat hyödyllisiä kortikaalisen katekoliamiini-neurotransmission modulaattoreina | |
| WO2015189830A9 (en) | Dual inhibitor compounds for use in the treatment of neurodegenerative disorders and alzheimer's disease | |
| MX2019010653A (es) | Inhibidores de beta secretasa. |